PMID- 17877542
OWN - NLM
STAT- MEDLINE
DCOM- 20080328
LR  - 20091103
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 9 Suppl 1
DP  - 2007 Sep
TI  - Screening and diagnosis of prediabetes: where are we headed?
PG  - 12-6
AB  - It is currently estimated that more than 300 million people have impaired glucose 
      tolerance (IGT), putting them at increased risk for type 2 diabetes mellitus 
      (T2DM) and its adverse consequences. In addition, many others are at risk on the 
      basis of a family history of T2DM, obesity, dyslipidaemia and hypertension. 
      Screening for risk should include both blood glucose testing in high-risk 
      populations and prescreening (e.g. by questionnaire, waist circumference 
      measurement) to identify high-risk individuals in overall low-risk populations; 
      these individuals should then undergo glucose testing. Fasting plasma glucose 
      measurement cannot diagnose IGT; the preferred definite test for diagnosis is 
      oral glucose tolerance testing.
FAU - Alberti, K G M M
AU  - Alberti KG
AD  - Department of Endocrinology and Metabolic Medicine, Imperial College, St Mary's 
      Hospital, London, UK. george.alberti@ncl.ac.uk
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Blood Glucose/*analysis
MH  - Diabetes Mellitus, Type 2/blood
MH  - Glucose Intolerance/blood/*diagnosis
MH  - Humans
MH  - Overweight
MH  - Prediabetic State/blood/*diagnosis
MH  - Risk Factors
RF  - 26
EDAT- 2007/10/18 09:00
MHDA- 2008/03/29 09:00
CRDT- 2007/10/18 09:00
PHST- 2007/10/18 09:00 [pubmed]
PHST- 2008/03/29 09:00 [medline]
PHST- 2007/10/18 09:00 [entrez]
AID - DOM764 [pii]
AID - 10.1111/j.1463-1326.2007.00764.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2007 Sep;9 Suppl 1:12-6. doi: 
      10.1111/j.1463-1326.2007.00764.x.